Liberate Bio’s CAR-M cell therapy almost completely depleted B-cells in a nonhuman primate study, the company said.
Chimeric antigen receptor T-cell therapy has exhibited “compelling” efficacy and safety in lupus, allowing 84% of patients to ...
Cabaletta Bio’s CAR-T cell therapy has eliminated the overreactive B cells of two patients with an autoimmune disease without preconditioning chemotherapy, pleasing investors and analysts while ...
6d
IN8bio Presents T cell Engager Data Demonstrating Deep B Cell Depletion for Autoimmune Indications
INB-619 demonstrated equivalent efficacy to the FDA approved, commercial T Cell Engagers (TCE) compounds, blinatumomab and ...
News-Medical.Net on MSN
Understanding age-related changes in T cells and vaccine response
As flu season approaches and public health officials roll out their annual push for vaccination, Allen Institute scientists ...
By profiling over 16 million immune cells from people aged 22 to 65 after flu vaccination, scientists discovered that memory ...
By analyzing the tumor environment of diffuse large B-cell lymphoma (DLBCL), researchers from The University of Texas MD ...
CD19 chimeric antigen receptor T-cell therapy improved lung function and skin thickness in patients with severe refractory ...
The first patient has been dosed in a Phase 1 trial testing the experimental CAR T-cell therapy obecabtagene autoleucel for progressive MS.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback